Onlikang announced that it recently received the “Drug Registration Certificate” for diclofenac sodium enteric tablets and the “Drug Supplement Application Approval Notice” for sacubatl valsartan sodium tablets issued by the State Drug Administration. The specification of diclofenac sodium enteric tablets is 25 mg. The approval number is valid until December 8, 2030, and is deemed to have passed the consistency evaluation; sacubatl valsartan sodium tablets were increased by 100 mg, and the approval number is valid until June 27, 2029. This approval will enrich the company's product pipeline and specifications, but drug sales are affected by policy, market and other factors, and there is uncertainty.

Onlikang announced that it recently received the “Drug Registration Certificate” for diclofenac sodium enteric tablets and the “Drug Supplement Application Approval Notice” for sacubatl valsartan sodium tablets issued by the State Drug Administration. The specification of diclofenac sodium enteric tablets is 25 mg. The approval number is valid until December 8, 2030, and is deemed to have passed the consistency evaluation; sacubatl valsartan sodium tablets were increased by 100 mg, and the approval number is valid until June 27, 2029. This approval will enrich the company's product pipeline and specifications, but drug sales are affected by policy, market and other factors, and there is uncertainty.